ARID1A Knockout HCT116 Cell Line

The choice depends on whether you are studying ARID1A (AT-rich interaction domain 1A, BAF250A)'s role as the principal BAF/SWI/SNF chromatin remodeling complex DNA-binding subunit or modeling ARID1A-mutated cancers for synthetic lethal therapy. The Knockout line is the standard tool for asking whether ARID1A is required for these processes — ARID1A is the principal SWI/SNF (BAF) complex DNA-binding subunit (one of ARID1A/ARID1B paralogs that are mutually exclusive in canonical BAF); ARID1A is one of the most frequently mutated tumor suppressors in cancer (~20% of all cancers, especially ovarian clear cell carcinoma, endometrial cancer, gastric cancer, hepatocellular carcinoma), typically with loss-of-function mutations. Overexpression is useful for studying ARID1A in heterologous expression contexts. For cancer biology and synthetic lethality research, the EDITGENE ARID1A Knockout in HCT 116 is uniquely valuable — HCT 116 is MSI-H colorectal cancer, providing a relevant context for ARID1A loss biology. Rescue with wild-type ARID1A is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐ ARID1A-mutant synthetic lethal approaches: ⭐⭐ EZH2 inhibitors (tazemetostat, FDA-approved for epithelioid sarcoma; in clinical development for ARID1A-mutant ovarian cancer based on tazemetostat-ARID1A synthetic lethal observations), ARID1B paralog dependency (single ARID1A loss creates dependency on ARID1B in BAF complex), and emerging ARID1A-mutated cancer therapeutic strategies.

Primary applications: • EZH2 inhibitor synthetic lethality: critical genetic control for ⭐⭐ tazemetostat (FDA-approved EZH2 inhibitor) — ARID1A-null cells show synthetic lethal hypersensitivity to EZH2 inhibition. • BAF complex composition: BAF complex subunit expression and assembly analysis in ARID1A-null cells. • ARID1B paralog dependency: ARID1A-null cells become dependent on ARID1B for residual BAF function (single-paralog dependency). • MSI-H/dMMR colorectal context: in HCT 116 MSI-H background, ARID1A's interaction with MMR pathway and immunotherapy. EDITGENE recommends this HCT 116-based ARID1A KO as a critical specificity control for ARID1A-mutant synthetic lethal cancer therapeutic development.

Yes, with considerations for this very large protein: • Construct design: ARID1A is a ~242 kDa BAF complex DNA-binding subunit with N-terminal ARID DNA-binding domain — full-length cDNA rescue is technically challenging due to large mRNA size. • Domain-focused rescue: ARID domain or specific regions can be used for targeted functional rescue. • BAF complex partnership: rescue interpretation considers other BAF subunits (SMARCA4/BRG1, SMARCB1, ARID1B) expression. • Cancer mutation rescue: rescue with patient-derived ARID1A mutations enables disease genotype-function studies. • Functional readout: rescue should restore BAF complex assembly and chromatin accessibility. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.